| Status | Awaiting development |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | TA |
| ID number | 6127 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 01 February 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 06 December 2022 | As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in early August 2023 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early October 2023. |
For further information on how we select topics for development, please see our page about topic selection